Upon request of a Health Care Professional (HCP) and with the approval from ANSM, lntsel Chimos provides compassionate access ta drugs that do not have a marketing authorization (MA) in France to allow HCP ta treat rare or serious pathologies that have reached a therapeutic impasse.
As part of its commitment to early access to innovation, lntsel Chimos is authorized to distribute products intended for human experimentation. This delicate operation requires specific expertise and is deeply embedded in ail stages of our supply chain.